$42.77
+1.52 (+3.68%)
Performance
1D
—
1W
—
1M
—
3M
+29.84%
6M
+163.36%
1Y
+135.52%
YTD
+39.86%
Open$42.03
Previous Close$41.25
Day High$44.08
Day Low$41.73
52W High$38.16
52W Low$10.91
Volume—
Avg Volume758.4K
Market Cap2.93B
P/E Ratio—
EPS$-2.55
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$33.24
Above
SMA 200
$22.06
Above
RSI (14)
64.7
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
21 analysts
Price Target
+84.5% upside
Current
$42.77
$42.77
Target
$78.92
$78.92
$58.92
$78.92 avg
$128.60
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 469.29M | 433.92M | 481.69M |
| Net Income | -23,759,261 | -24,167,490 | -23,392,315 |
| Profit Margin | -5.1% | -5.6% | -4.9% |
| EBITDA | -33,340,073 | -28,197,061 | -36,465,134 |
| Free Cash Flow | -26,670,161 | -19,444,681 | -29,871,207 |
| Rev Growth | +18.1% | +19.4% | +22.5% |
| Debt/Equity | 0.73 | 0.87 | 0.77 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $205.20 | +0.13% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $348.43 | -0.38% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.11 | +0.56% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $448.62 | -0.58% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $741.69 | +0.70% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $308.05 | +0.45% | 139.7 | 43.84B |